Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Bergemalm

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Plos One|July 21, 2010
Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patientsKarin Forsberg, P Andreas Jonsson, Peter M Andersen, et al.
Scandinavian Journal of Gastroenterology|August 20, 2021
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREGCarl Eriksson, Isabella Visuri, Lina Vigren, et al.
United European Gastroenterology Journal|July 14, 2022
Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality registerJoel Thunberg, Olle Björkqvist, Charlotte R H Hedin, et al.
Journal of Crohn'S & Colitis|December 1, 2022
Idiopathic Thrombocytopaenic Purpura associated with Inflammatory Bowel Disease: a multicentre ECCO CONFER case seriesHussein Mahajna, Bram Verstockt, Daniel Bergemalm, et al.
Journal of Crohn'S & Colitis|November 4, 2024
Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter StudyBenita Salomon, Padhmanand Sudhakar, Daniel Bergemalm, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Gastroenterology|July 23, 2021
Systemic Inflammation in Preclinical Ulcerative ColitisDaniel Bergemalm, Erik Andersson, Johan Hultdin, et al.
Journal of Crohn'S & Colitis|February 25, 2022
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2Jan K Nowak, Alex T Adams, Rahul Kalla, et al.
Journal of Crohn'S & Colitis|January 25, 2023
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel DiseaseArchana Shubhakar, Bas C Jansen, Alex T Adams, et al.
Scandinavian Journal of Gastroenterology|April 1, 2017
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Carl Eriksson, Jan Marsal, Daniel Bergemalm, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Plos One|July 21, 2010
Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patientsKarin Forsberg, P Andreas Jonsson, Peter M Andersen, et al.
Scandinavian Journal of Gastroenterology|August 20, 2021
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREGCarl Eriksson, Isabella Visuri, Lina Vigren, et al.
United European Gastroenterology Journal|July 14, 2022
Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality registerJoel Thunberg, Olle Björkqvist, Charlotte R H Hedin, et al.
Journal of Crohn'S & Colitis|December 1, 2022
Idiopathic Thrombocytopaenic Purpura associated with Inflammatory Bowel Disease: a multicentre ECCO CONFER case seriesHussein Mahajna, Bram Verstockt, Daniel Bergemalm, et al.
Journal of Crohn'S & Colitis|November 4, 2024
Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter StudyBenita Salomon, Padhmanand Sudhakar, Daniel Bergemalm, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Gastroenterology|July 23, 2021
Systemic Inflammation in Preclinical Ulcerative ColitisDaniel Bergemalm, Erik Andersson, Johan Hultdin, et al.
Journal of Crohn'S & Colitis|February 25, 2022
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2Jan K Nowak, Alex T Adams, Rahul Kalla, et al.
Journal of Crohn'S & Colitis|January 25, 2023
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel DiseaseArchana Shubhakar, Bas C Jansen, Alex T Adams, et al.
Scandinavian Journal of Gastroenterology|April 1, 2017
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)Carl Eriksson, Jan Marsal, Daniel Bergemalm, et al.
Pageof 5